Search Results
May 21, 2026, 23:30 ET Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
previously untreated populations, ORR was 87.5%, confirmed ORR was 80.0%, CR rate was 12.5% and DCR was 92.5%. The median progression-free survival (PFS) was 12.9 months, median duration of response (DoR) and median overall survival (OS) was not yet reached. No new safety signals related to 9MW2821 or
More news about: Mabwell
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
progression‑free survival (PFS) assessed by blinded independent central review (BICR), and the key secondary endpoint was overall survival (OS). As of September 29, 2025, the median follow-up was 10.5 months.The results demonstrated that：Significant PFS improvement: PFS assessed by BICR
More news about: Kelun-Biotech
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
(HR=0.55；95% CI：0.36-0.85)。預設亞組獲益一致：在PD-L1 TPS 1-49%及TPS≥50%患者中，PFS HR分別為0.28 (95% CI: 0.19-0.41)和0.47 (95% CI: 0.29-0.77)；在非鱗狀和鱗狀NSCLC患者中， PFS HR分別為0.28 (95% CI: 0.18-0.43)和0.44 (95% CI: 0.29-0.66)。安全性方面，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗組與帕博利珠單抗組≥3級治療期間不良事件(TEAEs)發生率分別為55.3%和31.4%。因不良事件
More news about: 科倫博泰
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg Q3W dose group, the median PFS reached 10.1 (95%CI 6.0, 14.0) months, and the median OS achieved 18.2 (95%CI 10.7, NE; maturity 48.4%) months, with a 24-month OS rate of 47.8% (95%CI
More news about: Innovent Biologics
May 21, 2026, 18:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68
More news about: Pomerantz LLP
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
presentations at ASCO and EHA include:In the Phase 3 AcceleRET clinical trial, pralsetinib met the primary progression-free survival (PFS) endpoint and had a significantly greater overall response rate and more durable response vs. standard of care, demonstrating the clinical utility of
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:00 ET Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Long-term follow-up reinforces PFS and OS benefit of lucicebtide plus standard of care in ndGBM: mPFS projected at 28.4 months, mOS not yet reached with 6 of 9 patients alive TARRYTOWN, N.Y., May 21, 2026
More news about: Sapience Therapeutics, Inc.
May 21, 2026, 17:00 ET Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
combination of therapy demonstrates an objective response rate (ORR) of 55%, disease control rate (DCR) of 95%, and median progression-free survival (PFS) of 10.6 months. Patients with HER2 IHC 3+ tumor cell proportions ≥10%, as identified by AI analysis, achieve substantially higher response rates compared
More news about: Lunit
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
response, 66% partial response).5Median duration of response (mDoR) and median progression‑free survival (PFS) were not yet reached, with 6‑ and 9‑month PFS rates of 78% and 62%, respectively.5Overall, the safety profile of the combination was generally consistent with
More news about: Boehringer Ingelheim
May 21, 2026, 17:00 ET Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
presentation on May 31 at 4:36 p.m. CDT. Key findings from more than three years of follow-up data further support the robust progression-free survival (PFS) and time to next treatment intervention (TTNI) results observed with VORANIGO in previous analyses and confirm the durable and sustained treatment benefit
More news about: Servier Pharmaceuticals
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
early stage disease. Two independent primary endpoints of the study are PFS and OS. At this pre-specified interim analysis, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS. OS data are immature, a positive trend is currently observed. Follow-up
More news about: Kelun-Biotech
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Australia.Participants are randomized 1:1 to receive once-daily oral rocbrutinib (200 mg) or pirtobrutinib (200 mg). The primary endpoint is progression-free survival (PFS), and secondary endpoints include overall survival (OS, key secondary endpoint), overall response rate (ORR), and duration of response (DOR), time to
More news about: Lupeng Pharmaceutical Ltd
May 21, 2026, 07:30 ET MAYFAIR GOLD ADVANCES DISTRICT-SCALE EXPLORATION STRATEGY
mineral resource of gold (181.3Mt at an average grade of 0.74 g/t) and was advanced toward development through a positive Pre-Feasibility Study (the "PFS") released in January 2026.1The consolidated land package is located along and adjacent to the Porcupine–Destor Fault Zone ("PDFZ"),
More news about: Mayfair Gold Corp.
May 21, 2026, 06:00 ET Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
presented at the 2025 European Society for Medical Oncology (ESMO) Congress. As of the PFS final analysis cutoff of February 17, 2025, the median follow-up was 16.6 months. The median PFS as assessed by BICR was 22.2 months with sintilimab plus fruquintinib, compared to 6.9 months with axitinib/everolimus
More news about: Innovent Biologics
May 20, 2026, 09:15 ET With Gold Above $4,500 and Crews on the Ground, This Permitted Tanzanian Developer Just Closed Its Funding Stack
therefore is not independent of the Company. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: USA News Group
May 20, 2026, 08:00 ET Kinterra Capital Secures US$75 Million to Advance White Pine Copper to FID Following PFS Progress and Royalty Framework Update
development spearheaded by Kinterra at the Project, which is culminating into an updated pre-feasibility study ("PFS") that demonstrates exceptional project economics at long-term consensus pricing. The PFS will be complete in early Q326. Alongside the progression of key project development work, Kinterra has
More news about: Kinterra Capital Corp
May 20, 2026, 01:54 ET AstraZeneca dan Roche Diagnostics Asia Pacific Pacific Perkuat Pengembangan Patologi Digital Berbasis AI untuk Kanker Payudara dan Paru
memperoleh manfaat klinis seperti peningkatan tingkat respons, memperpanjang kelangsungan hidup tanpa progresi penyakit (progression-free survival/PFS), [9] serta penggunaan sumber daya layanan kesehatan yang lebih optimal."Diagnosis yang cepat dan akurat merupakan fondasi utama
More news about: AstraZeneca
May 19, 2026, 09:45 ET Rock Tech Advances Georgia Lake Lithium Project, Identifies Potential Pathway to Reduce Processing CAPEX by Up to 50 per cent
tonnes at 1.00 per cent Li₂O.The PFS estimated a pre-tax NPV of USD$223 million, an after-tax NPV of USD$146 million, a pre-tax IRR of 47.8 per cent, and an after-tax IRR of 35.6%, based on an average life-of-mine SC6 price of USD$1,500 per tonne. The PFS also estimated pre-production capital costs
More news about: Rock Tech Lithium Inc.
May 19, 2026, 09:00 ET REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations
management was "hopeful" for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS" and an "opportunity to have … a statistically significant, clinically meaningful benefit on OS."A little more than two months later, on May 16,
More news about: SueWallSt.com
May 18, 2026, 07:54 ET Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
Rate (ORR), with key secondary endpoints including the measurement of investigator-assessed Clinical Benefit Rate (CBR) and Progression Free Survival (PFS).About BTX-9341BTX-9341 is a first-in-class, oral degrader of CDK4/6, important targets for a range
More news about: Biotheryx, Inc.
May 14, 2026, 19:03 ET SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
activity across a broader patient population. Across Phase 2, key efficacy endpoints including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be assessed to generate the clinical evidence necessary to support regulatory review process.The advancement
More news about: SN BioScience Inc
May 14, 2026, 16:02 ET Inhibrx Reports First Quarter 2026 Financial Results
(CPS) ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).We plan to announce progression-free survival (PFS) data from the randomized Phase 2 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026.ozekibart (INBRX-109)
More news about: Inhibrx Biosciences, Inc.
May 14, 2026, 13:25 ET LODE GOLD'S NEW MINERAL RESOURCE ESTIMATE: 1.11 MOZ OF GOLD - 18.8 MT AT 1.84 G/T AU (MEASURED & INDICATED) AND 1.99 MOZ OF GOLD (INFERRED) - 33.1 MT AT 1.86 G/T AU AT FREMONT GOLD MINE
classification of gold resources. The reclassification to M&I category is one of the key steps in derisking the project as we advance towards PFS, evaluating various optimized underground mining methods."Enhanced Geological Model and Data IntegrationThe updated resource
More news about: Lode Gold Resources Inc
May 14, 2026, 10:57 ET Inside America's Largest Conventional Measured and Indicated Uranium Deposit: Eagle Nuclear Energy Advances Aurora Toward Pre-Feasibility
Corp.Environmental baseline studies commence at flagship Aurora Uranium Project ahead of 27,000-foot, 47-hole drill program scheduled to commence in July 2026; PFS targeted second half of 2027NEW YORK, May 14, 2026 /PRNewswire/
More news about: Equity Insider
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
refusal, or treatment is no longer in the best interest of the patient. Patients are followed for 12 months to determine progression free survival (PFS) and overall survival (OS). More details can be found on clinicaltrials.gov with the identifier:
More news about: Market News Updates